home / stock / ganx / ganx news

GANX News and Press, Gain Therapeutics Inc. From 04/12/23

Stock Information
Company Name: Gain Therapeutics Inc.
Stock Symbol: GANX
Market: NASDAQ
Website: gaintherapeutics.com
Menu
GANX GANX Quote GANX Short GANX News GANX Articles GANX Message Board
Get GANX Alerts

News, Short Squeeze, Breakout and More Instantly...
GANX - Gain therapeutics appoints Evan Ballantyne as chief financial officer

2023-04-12 16:41:55 ET Gain Therapeutics ( NASDAQ: GANX ) said it had appointed Evan Ballantyne as the Chief Financial Officer. Ballantyne is expected to succeed Salvatore Calabrese's role, and during a reasonable transition period, Calabrese will remain employed by the c...
GANX - Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballant...

GANX - Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

BETHESDA, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the presentation of new pre-clinic...

GANX - Gain Therapeutics GAAP EPS of -$1.48 beats by $0.03, revenue of $0.14M beats by $0.02M

2023-03-23 16:41:15 ET Gain Therapeutics press release ( NASDAQ: GANX ): FY GAAP EPS of -$1.48 beats by $0.03 . Revenue of $0.14M (-12.5% Y/Y) beats by $0.02M . For further details see: Gain Therapeutics GAAP EPS of -$1.48 beats by $0.03, revenue of $0.14...
GANX - Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

Company expects completion of IND-enabling studies of GT-02287 in H1 2023 Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease expected by mid-year 2023 $22.1 million in cash and cash equivalents and marketable securities as of ...

GANX - Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

BETHESDA, Md., March 22, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel allosteric binding site...

GANX - Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program

BETHESDA, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced th...
GANX - Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

BETHESDA, Md., March 09, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and...

GANX - Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium

BETHESDA, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and ...

GANX - Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences

BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and ...
Previous 10 Next 10